Novo Nordisk Secures Oral Obesity Candidate in $2.6 Billion Hengrui Licensing Pact

Novo Nordisk pays $300M upfront for worldwide rights to Hengrui's oral obesity tablet HRS-1596, with the deal potentially worth $2.6B.

Novo Nordisk has moved to deepen its metabolic-disease pipeline, locking up worldwide licensing rights to an experimental oral obesity drug from China's Jiangsu Hengrui Pharmaceuticals. The Danish drugmaker will pay $300 million upfront for HRS-1596, a dual GLP-1/GIP receptor agonist designed as a once-weekly tablet, with the deal's total value capable of reaching $2.6 billion should clinical, regulatory and commercial milestones be met.

The agreement grants Novo Nordisk exclusive rights to develop, manufacture and commercialize the molecule outside mainland China, Hong Kong, Macau and Taiwan. Milestone payments tied to future progress account for up to $2.3 billion of the headline figure, and the two companies have also agreed on royalties against future sales. Closing is anticipated in the fourth quarter of 2026, subject to customary regulatory clearances including US antitrust approval.

Phase I Clearances Already in Hand

HRS-1596 targets obesity and potentially type 2 diabetes, and Chinese authorities have already cleared the start of first Phase I trials. The tablet format positions Novo Nordisk to compete for patient-friendly alternatives to the injectable therapies that currently dominate the market. Nordnet's Per Hansen cautioned, however, that even with favorable data, a market-ready product is likely seven to nine years away.

The Hengrui tie-up follows a separate global licensing arrangement struck with Nanexa, giving Novo Nordisk access to atomic layer deposition technology for drug delivery. That partnership carries a potential volume of up to EUR 1.165 billion.

CagriSema Delivers 12.4% Weight Loss

Progress on the company's own candidates is also accumulating. On 21 September, Novo Nordisk reported Phase 3 results from the REIMAGINE 5 trial of CagriSema, in which participants achieved average weight loss of 12.4%, compared with 9.1% in the comparator arm receiving 5 mg tirzepatide.

Beyond its therapeutic core, the group extended its collaboration with UNICEF on 22 September, committing a total of $18 million for the 2026–2030 period. The initiative is intended to reach more than 80 million children across seven countries with early obesity-prevention measures.

Buyback Proceeds at Average of 280.95 DKK

Alongside the pipeline investments, Novo Nordisk continues to repurchase its own shares. The average purchase price came in at 280.95 DKK per share, corresponding to a total value of DKK 9,939,842,031.

The combination of billion-dollar licensing commitments and an extensive buyback program underscores how aggressively management is defending its position in the fiercely contested incretin sector.

Shares Slip as UBS Stays Neutral

Market reaction to the latest licensing news was muted. Novo Nordisk shares traded 0.7% lower at EUR 33.80, extending year-to-date losses to 23%. While the Hong Kong-listed shares of its licensing partner advanced on news of the agreement, investors in the Danish group are weighing the opportunity against the lengthy development cycles that characterize the crowded obesity field.

Analyst opinion remains split on the road ahead. UBS reaffirmed its neutral "Hold" rating on 22 September.

The HRS-1596 acquisition marks another step in the race to deliver user-friendly dosage forms in the obesity market. Whether the substantial upfront and milestone outlays ultimately pay off will depend on the outcome of the clinical phases still to come.